Changxi Pharmaceutical Teams Up with Huadong Medicine to Commercialize CXG87 in China

Hangzhou Changxi Pharmaceutical has entered an exclusive commercialization collaboration with Huadong Medicine for its innovative respiratory therapy, CXG87 (modified budesonide/formoterol inhalation powder), in mainland China.

CXG87: A Next-Gen Inhaled Therapy

CXG87 is a Class 2.2 novel drug independently developed by Changxi for respiratory diseases like asthma. Key advantages include:

• Lower flow rate dependence, making it easier for patients with limited inspiratory flow.
• Single-dose powder inhaler, reducing misuse and ensuring consistent therapeutic performance.
• Phase III clinical trial completed enrollment, with NDA submission expected in H1 2026.

“CXG87 is the first product developed on our unique VFC platform and highlights both its scientific and commercial value.”

• Dr. Donghao Chen, founder & CEO of Changxi Pharmaceuticals.

Strategic Partnership

Under the agreement:

• Changxi Pharmaceutical will handle R&D, registration, production, and supply.
• Huadong Medicine will lead commercial promotion in China.

“Leveraging our nationwide network and expertise, CXG87 is expected to achieve rapid market access and broad patient coverage.”

• Lv Liang, chairman of Huadong Medicine.

Clinical and Commercial Impact

CXG87 aims to benefit asthma patients with inspiratory airflow limitations, offering a more reliable alternative to existing therapies like Symbicort Turbuhaler. This collaboration ensures accelerated access to innovative respiratory care for patients across China.

About the Companies

Changxi Pharmaceuticals: A clinical-stage biotech focused on innovative dry powder inhalers (DPI), built on proprietary pulverization/mixing and spray-drying platforms.

Huadong Medicine: Founded in 1993, it operates across the entire pharmaceutical value chain, including R&D, commercial operations, medical aesthetics, and industrial microbiology, with over 30 years of industry expertise.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!